SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 25, 2002; DOI 10.1182/blood-2002-05-1401. This Article Abstract Full Text (PDF) All Versions of this Article: 2002-05-1401v1 100/12/4033    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dong, J.-f. Articles by López, J. A. Search for Related Content PubMed PubMed Citation Articles by Dong, J.-f. Articles by López, J. A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2002, Vol. 100, No. 12, pp. 4033-4039 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions Jing-fei Dong, Joel L. Moake, Leticia Nolasco, Aubrey Bernardo, Wendy Arceneaux, Corie N. Shrimpton, Alicia J. Schade, Larry V. McIntire, Kazuo Fujikawa, and José A. López From the Thrombosis Research Section, Department of Medicine, and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Department of Biochemistry, University of Washington, Seattle; and the Cox Laboratory for Bioengineering, Rice University, Houston, TX.     Abstract Top Abstract Introduction Patients, materials, and... Results Discussion References Thrombotic thrombocytopenic purpura (TTP) is a devastating thrombotic disorder caused by widespread microvascular thrombi composed of platelets and von Willebrand factor (VWF). The disorder is associated with a deficiency of the VWF-cleaving metalloprotease, ADAMTS-13, with consequent accumulation of ultralarge (UL) VWF multimers in the plasma. ULVWF multimers, unlike plasma forms of VWF, attach spontaneously to platelet GP Ib, a component of the GP Ib-IX-V complex. We have found that ULVWF multimers secreted from stimulated endothelial cells (ECs) remained anchored to the endothelial surface where platelets and Chinese hamster ovary cells expressing the GP Ib-IX-V complex attached to form long beads-on-a-string structures in the presence of fluid shear stresses in both the venous (2.5 dyne/cm2) and arterial (20 and 50 dyne/cm2) ranges. Although measurement of the activity of the ADAMTS-13 VWF-cleaving metalloprotease in vitro requires prolonged incubation of the enzyme with VWF under nonphysiologic conditions, EC-derived ULVWF strings with attached platelets were cleaved within seconds to minutes in the presence of normal plasma (containing approximately 100% ADAMTS-13 activity) or in the presence of partially purified ADAMTS-13. By contrast, the strings persisted for the entire period of perfusion (10 minutes) in the presence of plasma from patients with TTP containing 0% to 10% ADAMTS-13 activity. These results suggest that cleavage of EC-derived ULVWF multimers by ADAMTS-13 is a rapid physiologic process that occurs on endothelial cell surfaces. (Blood. 2002;100:4033-4039) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients, materials, and... Results Discussion References von Willebrand factor (VWF) is a large plasma glycoprotein involved in several processes key to normal hemostasis. VWF that becomes affixed to the subendothelial matrix mediates the initial adhesion of platelets at sites of endothelial denudation by binding the platelet GP Ib-IX-V complex. VWF also plays a crucial role in the fluid-phase aggregation of platelets that occurs at sites of very high shear stress, initiating platelet activation through a shear-induced interaction with GP Ib-IX-V and also serving as the glue that holds the platelets together by binding the activated form of integrin IIb3. VWF is also involved in maintenance of the soluble coagulation system, binding coagulation factor VIII and thereby stabilizing it from degradation. VWF is synthesized in only 2 sites: in megakaryocytes, where it is stored in -granules that are later partitioned into platelets, and in endothelial cells, where it is either secreted constitutively or stored in granules called Weibel-Palade bodies for secretion on endothelial stimulation. VWF undergoes a number of intracellular processing steps after synthesis of the 2791-amino acid precursor protein.1 In the endoplasmic reticulum, the precursors form disulfide-linked dimers through C-terminal cysteine residues. After transport to the Golgi, the dimers join through N-terminal disulfide bonds to form multimers, in a process requiring the participation of the 741-amino acid propeptide, which is then cleaved by a furinlike enzyme before trafficking of the VWF into storage granules.2,3 It is unknown what limits the growth of multimers, or what determines their ultimate length. After multimerization, a portion of the VWF is stored in the endothelial Weibel-Palade bodies or platelet -granules, from where they are released on stimulation of the respective cells. Stored and newly secreted VWF is rich in ultralarge (UL) forms, which are hyperreactive in their capacity to bind the GP Ib-IX-V complex.4 On their secretion, ULVWF multimers are processed further, by limited proteolysis by a recently characterized plasma metalloprotease called ADAMTS-13. ADAMTS-13 reduces the size of large and ultralarge5-7 VWF multimers to smaller forms in vitro by specifically cleaving the Y842/M843 peptide bond in the VWF A2 domain, generating 176-kDa and 140-kDa fragments that are found in the normal circulation.8-10 ADAMTS-13 activity is currently measured in vitro by using static assays that require prolonged incubation (up to 24 hours) under nonphysiologic conditions (low ionic strength buffer containing barium ion and urea or guanidine at a pH of 8-9).10 The inefficiency of this reaction suggests that the in vitro assays lack one or more conditions that allow rapid proteolytic cleavage of ULVWF multimers in vivo. The importance of this proteolytic processing is perhaps best illustrated by the severe consequences of ADAMTS-13 deficiency, which is associated with a severe thrombotic disorder known as thrombotic thrombocytopenic purpura (TTP). TTP is characterized by microvascular thrombosis, consumptive thrombocytopenia, organ ischemia, and hemolytic anemia.11,12 The microthrombi are composed of platelets and von Willebrand factor (VWF).11 If left untreated, the disorder is rapidly progressive and almost uniformly fatal. In the current study, we observed that ULVWF multimers secreted from endothelial cells (ECs) are anchored to the endothelial surface as extraordinarily long stringlike structures capable of binding platelets and Chinese hamster ovary (CHO) cells that express surface GP Ib. These ULVWF multimeric strings were cleaved rapidly in the presence of normal plasma or partially purified ADAMTS-13, but not by plasma from any of the 14 patients with TTP.     Patients, materials, and methods Top Abstract Introduction Patients, materials, and... Results Discussion References Platelet and plasma preparations Under a protocol approved by the Institutional Review Board of the Baylor College of Medicine, blood was drawn from 34 healthy donors who had no history of thrombosis and had not ingested medications in the 2 weeks preceding phlebotomy. All donors signed consent forms before blood was drawn. The donor pool consisted of 19 women and 15 men, ranging in age from 22 to 56 years. Blood was drawn into acid-citrate dextrose (ACD) anticoagulant (85 mM sodium citrate, 111 mM glucose, and 71 mM citric acid, 10% vol/vol). To isolate platelets, the whole blood was first centrifuged at 150g for 15 minutes at 24°C to obtain platelet-rich plasma (PRP), which was then centrifuged at 900g for 10 minutes to obtain platelets and platelet-poor plasma (PPP). The platelet pellets were washed once with a CGS buffer (13 mM sodium citrate, 30 mM glucose, and 120 mM sodium chloride, pH 7.0) and resuspended in Ca++, Mg++-free Tyrode buffer (138 mM sodium chloride, 5.5 mM glucose, 12 mM sodium bicarbonate, 2.9 mM potassium chloride, and 0.36 mM dibasic sodium phosphate, pH 7.4). PRP was also used in some experiments. TTP patients Plasma from 14 patients with TTP was obtained from both citrated and ACD blood (Table 1). Among them, 4 patients carried the diagnosis of familial chronic relapsing TTP of childhood and 10 carried the diagnosis of adult acquired idiopathic TTP. Of those with adult TTP, the presence of ADAMTS-13 inhibitors was documented in 3 patients. The VWF-cleaving activity in these patients' plasmas ranged from 0% to 10% as determined by a standardized static assay that used ULVWF from the supernatant of histamine-stimulated ECs as a substrate.10,13                                View this table: [in this window] [in a new window]   Table 1. Information about the TTP patients Endothelial culture Under a protocol approved by the Institutional Review Board of the Baylor College of Medicine, endothelial cells were obtained from human umbilical veins (HUVECs) or arteries (HUAECs) as described previously.14 The umbilical cords were first washed with phosphate buffer (140 mM NaCl, 0.4 mM KCl, 1.3 mM NaH2PO4, 1.0 mM Na2HPO4, 0.2% glucose, pH 7.4) and then infused with a collagenase solution (0.02%; Invitrogen Life Technologies, Carlsbad, CA). After a 30-minute incubation at room temperature, the cords were rinsed with 100 mL phosphate buffer. Eluates containing endothelial cells were centrifuged at 250g for 10 minutes. The cell pellets were resuspended in Medium 199 (Invitrogen Life Technologies) containing 20% heat-inactivated fetal calf serum and 0.2 mM L-glutamine. The endothelial cells were then plated on a culture dish coated with 1% gelatin and grown until confluent (3-5 days). Endothelial cells from human coronary artery (HCAEC) and human microvasculature (HMVEC) were purchased from Cambrex (East Rutherford, NJ) and cultured in endothelial growth medium containing bovine brain extract, human epidermal growth factor, hydrocortisone, GA-1000 (gentamicin and amphotericin B), and fetal bovine serum (2%). Cells were maintained according to the manufacturer's instructions and used within 4 to 5 passages. We also used a human endothelial cell line (ECV304) defective in VWF synthesis in some of the studies. This cell line is derived from human umbilical vein endothelial cells15 and was shown to be of endothelial origin by the presence of Weibel-Palade bodies and positive staining for the endothelial marker PHM5. Endothelial cells were activated with 25 µM histamine (Sigma-Aldrich, St Louis, MO) for 10 minutes at room temperature before the perfusion experiments. Parallel-plate flow chamber The formation and cleavage of VWF strings was studied under flow in a parallel-plate flow chamber system and observed by phase-contrast video microscopy. The parallel-plate flow chamber is composed of a polycarbonate slab, a silicon gasket, and a glass coverslip.16 The endothelial cells are grown as a monolayer on the coverslip.17 A syringe pump connected to the outlet port draws the platelet suspension through the chamber at defined flow rates to generate specific wall shear stresses. Shear stresses of 2.5, 20, and 50 dyne/cm2 were used in the experiments reported here. The chamber was kept at 37°C with a thermostatic air bath during the experiments. The assembled parallel-plate flow chamber was mounted onto an inverted-stage microscope (Eclipse TE300; Nikon, Garden City, NY) equipped with a high-speed digital camera (Model Quantix; Photometrics, Tucson, AZ). Acquired images were analyzed offline by using MetaMorph software (Universal Images, West Chester, PA). The strings were quantitated by counting individual strings in 20 continuous view fields (× 400). ADAMTS-13 ADAMTS-13 was purified to the diethylaminoethyl (DEAE) column step from factor VIII/VWF concentrate by the method described earlier.6 Purified ADAMTS-13 slowly cleaved VWF in overnight incubation in the presence of 1 M urea, yielding only 176-kDa and 140-kDa fragments as detected on reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. Antibodies The anti-VWF monoclonal antibody 6G1, which blocks the binding of GP Ib, was a kind gift from Michael C. Berndt of the Baker Medical Research Institute, Melbourne, Victoria, Australia. AK2, a GP Ib monoclonal antibody that blocks VWF binding, was purchased from RDI (Flanders, NJ). Polyclonal anti-VWF was purchased from DAKO (Carpinteria, CA).     Results Top Abstract Introduction Patients, materials, and... Results Discussion References CHO cells expressing the GP Ib-IX complex align in stringlike structures on the surface of histamine-stimulated HUVECs While investigating the role of the GP Ib-IX complex in platelet-endothelial interactions, we observed that when CHOIX cells (expressing the GP Ib-IX-V complex) were perfused over histamine-stimulated HUVECs (at 2.5 dyne/cm2 shear stress), adherent cells sometimes aligned in the direction of flow, forming beads-on-a-string structures that moved back and forth in the fluid stream as if connected by an invisible string (Figure 1A). There were typically between 5 and 10 cells per string. In contrast, when CHOIX cells, which lack GP Ib, were perfused over the activated endothelial cells, they neither adhered nor formed strings (Figure 1B). Further, formation of the stringlike structures required endothelial activation. View larger version (65K): [in this window] [in a new window]   Figure 1. Adhesion of CHO cells on stimulated endothelial cells. CHO cells expressing either the GP Ib-IX-V complex (CHOIX cells) or a partial complex lacking GP Ib (CHOIX cells) were perfused at a constant shear stress of 2.5 dyne/cm2 over a monolayer of HUVECs. CHOIX cells (A), but not CHOIX cells (B), adhered to endothelial cells in a stringlike fashion. The figure is representative of 5 separate experiments. Original magnifications × 200. Platelets also adhere to long strings attached to stimulated endothelial cells To determine the potential physiologic relevance of the GP Ib-interactive strings, we performed the same experiments with washed platelets. Washed human platelets perfused over a monolayer of histamine-stimulated HUVECs at 2.5 dyne/cm2 shear stress adhered to and formed similar beads-on-a-string structures on the endothelial surface (Figure 2Ai). These structures only formed on the stimulated (Figure 2Ai) but not unstimulated ECs (Figure 2Aii). They moved together back and forth in the fluid stream (Figure 2B). In some cases, the strings were astonishingly long, holding tens or even hundreds of platelets, and having lengths up to several millimeters (Figure 2C). We did not observe the formation of VWF-platelet strings on the endothelial surface that had previously been perfused with normal plasma (data not shown). View larger version (89K): [in this window] [in a new window]   Figure 2. Platelet adhesion on stimulated endothelial cells. Washed normal platelets were perfused at a constant shear stress of 2.5 dyne/cm2 over a monolayer of HUVECs. (A) Long lines of platelets aligned as "beads on a string" above histamine-stimulated (i), but not unstimulated (ii), HUVECs. Original magnification × 400. (B) Platelet strings repeatedly stretch and relax in the fluid stream. (C) The length of strings varied but could be several millimeters long (bar = 100 µm). The figure is representative of 86 separate experiments using HUVECs and platelets from 34 different donors. Long strings are ULVWF multimers To determine whether the strings were truly composed of ULVWF, we evaluated platelet attachment to the strings in the presence of monoclonal antibodies that block the GP Ib-VWF interaction: either 6G1, which binds VWF, or AK2, which binds GP Ib. Under conditions identical to those used to induce platelet binding to the endothelial strings in the absence of antibody, both antibodies completely inhibited platelet binding (Figure 3A-B), whereas a control immunoglobulin G (IgG) did not (Figure 3C). Experiments with a transformed endothelial cell line (ECV304) that is defective in VWF synthesis provided further evidence that the strings are made up of VWF, as platelets did not form stringlike structures on histamine-stimulated ECV304 (Figure 3D).15 Finally, polystyrene beads coated with a polyclonal anti-VWF antibody also attached to the long strings when perfused over stimulated ECs (Figure 3E), confirming that the strings are indeed composed of the EC-derived ULVWF. View larger version (90K): [in this window] [in a new window]   Figure 3. The strings were formed by tethering platelets to ultralarge VWF multimers via GP Ib of the GP Ib-X complex. The formation of strings with adherent platelets was blocked by monoclonal antibodies against either VWF (6G1; A) or GP Ib (AK2; B) but not by a control mouse IgG (C). Original magnifications × 400. The platelet strings did not form above the surface of endothelial cells incapable of VWF synthesis (ECV304; D). Polystyrene beads coated with a polyclonal anti-VWF antibody also adhered in strings on activated HUVECs (E). Each figure is representative of 4 to 6 separate experiments. Influence of fluid shear stress and endothelial cell type on the formation of ULVWF multimeric strings The experiments until now examined string formation at venular shear stresses. It was, therefore, important to determine whether the platelets would attach and also form beads-on-a-string structures on ULVWF at arterial or arteriolar shear stresses, where the GP Ib-VWF interaction is believed to be more important for achieving hemostasis and also where the platelet-VWF thrombi characteristic of TTP are known to form. Washed platelets were perfused over the stimulated endothelial cells under shear stresses of 20 or 50 dyne/cm,2 both of which are often encountered in the arterial circulation.18 The VWF strings also formed under these conditions (Figure 4), although the numbers of strings formed on the endothelial surface were lower under both 20 and 50 dyne/cm2 of shear stress than at 2.5 dyne/cm,2 a shear stress normally found in venules. These results demonstrate that the ULVWF strings form under conditions of both low-shear venous flow and high-shear arterial flow. View larger version (11K): [in this window] [in a new window]   Figure 4. Formation of ULVWF strings under various conditions of shear stress. Washed platelets were perfused over histamine-stimulated HUVECs at flow rates that generated fluid shear stresses of 2.5, 20, or 50 dyne/cm2. Formation of the ULVWF strings with adherent platelets was evaluated at the end of 2 minutes of perfusion and quantified in 20 continuous view fields (× 400). The results are expressed as means ± SEM, * Student t test, n = 4, P < .05. To determine if the formation of the VWF strings is unique to HUVECs, we have also tested cells from arterial endothelium. Primary cultures of human endothelial cells from umbilical artery or from early passages (4-5 passages) of coronary artery endothelium and lung microvascular endothelium were stimulated with 25 µM histamine to induce release of ULVWF. Perfused washed human platelets adhered to attached ULVWF multimers on each of the different endothelial cell types (Figure 5). The numbers of ULVWF strings that formed on histamine-stimulated primary cultures of endothelial cells from umbilical veins or arteries were significantly greater than those formed on the coronary or microvascular endothelial cells (Figure 5). It is unknown whether this decrease is a result of the higher passage number of the latter cell types, a well-known determinant of VWF production, or represents an inherent difference in VWF production between the endothelia of different vascular beds. View larger version (11K): [in this window] [in a new window]   Figure 5. Formation of ULVWF strings on different types of endothelial cells. Washed normal platelets were perfused over histamine-stimulated endothelial cells from human umbilical veins (HUVECs) and arteries (HUAECs), as well as from coronary arteries (HCAECs) and lung microvasculature (HMVECs), under a shear stress of 2.5 dyne/cm2. Formation of ULVWF strings with adherent platelets was evaluated after 2 minutes of perfusion and quantified in 20 continuous view fields (× 400). The results are expressed as means ± SEM, * Student t test, n = 7, P < .05. Long ULVWF strings are cleaved by ADAMTS-13 present in normal plasma In the previous experiments, the platelets that adhered to the ULVWF strings were in plasma-free buffer. When platelet-rich plasma instead of washed platelets in buffer was perfused over stimulated HUVECs, the ULVWF strings with adherent platelets either never formed or were cleaved instantaneously (Figure 6B). In addition, when preformed ULVWF strings with adherent platelets were perfused with platelet-poor plasma from any of the 34 healthy donors, all strings were cleaved within 2 minutes (Figure 6C-D). The strings were usually cleaved in 1 or 2 steps at or near their upstream attachment sites, releasing the ULVWF multimers with adherent platelets. We did not observe the reformation of the platelet-VWF strings on the endothelial surface that had previously been treated with either normal plasma or partially purified ADAMTS-13 (data not shown). View larger version (76K): [in this window] [in a new window]   Figure 6. Normal plasma contains VWF-cleaving activity. The ULVWF strings with adherent platelets formed when washed platelets (A), but not platelet-rich plasma (B), were perfused over histamine-stimulated HUVECs. The ULVWF strings with adherent platelets that formed by perfusing washed platelets (C; arrow) were cleaved when normal platelet-poor plasma was perfused subsequently (D; arrow). The figure is representative of 28 separate experiments. Original magnifications × 400. The rapid cleavage of the ULVWF-platelet strings in the presence of normal plasma suggested that this might be the action of the recently characterized metalloprotease, ADAMTS-13. To examine this possibility more closely, we perfused a buffered solution containing ADAMTS-13 through the chamber containing preformed ULVWF-platelet strings. The strings were cleaved rapidly from the HUVEC surface at a rate similar to that observed with normal plasma (Figure 7). The VWF-cleaving activity of the partially purified protease was determined as previously described.8 View larger version (13K): [in this window] [in a new window]   Figure 7. Cleavage of the ULVWF strings with adherent platelets by normal plasma, TTP plasma, or ADAMTS-13. Washed normal platelets were perfused over histamine-stimulated HUVECs at 2.5 dyne/cm2 shear stress for 2 minutes to allow formation of ULVWF strings with adherent platelets. Then, either Tyrode buffer, normal plasma, TTP plasma, or partially purified VWF-cleaving metalloprotease was perfused for an additional 2 minutes (for normal plasma and purified VWF-cleaving metalloprotease) or 10 minutes (for buffer or TTP plasma). The number of ULVWF strings with adherent platelets was quantified in 20 continuous view fields (× 400), and the results are expressed as means ± SEM. ULVWF strings are not cleaved in the presence of plasma from TTP patients Because defects in ADAMTS-13 metalloprotease have been proposed as the cause of TTP,12 we tested the capacity of plasma from patients with TTP to cleave the VWF strings. Citrated plasma samples from 14 patients with TTP were evaluated. Each plasma sample contained less than 10% of normal VWF-cleaving metalloprotease activity, as determined by a static assay described previously.19,20 Washed normal platelets were suspended in the individual TTP plasma samples and perfused over histamine-stimulated HUVECs. In contrast to the rapid cleavage of ULVWF multimers in the presence of normal plasma (Figure 8B) or partially purified ADAMTS-13 (Figure 7), the ULVWF multimeric strings with adherent platelets were not cleaved in the presence of TTP plasma during the entire 10-minute period of monitoring (Figures 7 and 8A). View larger version (107K): [in this window] [in a new window]   Figure 8. Plasma from patients with TTP did not cleave the ULVWF strings with adherent platelets. The ULVWF strings with adherent platelets remained after 10 minutes of perfusion at 2.5 dyne/cm2 of plasma from patients with TTP (A), whereas the strings were rapidly cleaved when normal plasma was perfused (B). The figure is representative of separate experiments carried out using plasma from 14 patients with TTP or 34 healthy donors. Original magnifications × 400. When a mixture (1:1 ratio) of the partially purified ADAMTS-13 (or normal plasma) and plasma from 2 patients with adult acquired idiopathic TTP containing anti-ADAMTS-13 antibodies was perfused over the stimulated ECs, the VWF strings formed (Figure 9C,E) on the endothelial surface at levels comparable to those perfused with buffer (Figure 9A). In contrast, deficiency in the ADAMTS-13 activity in plasma from 2 patients with familial TTP was corrected by mixing with normal plasma (1:1 volume ratio) or with partially purified ADAMTS-13 (Figure 9D-E). View larger version (27K): [in this window] [in a new window]   Figure 9. Effect of TTP plasma on the ULVWF-cleaving activity of ADAMTS-13. Washed platelets suspended in Tyrode buffer formed the stringlike structures on the stimulated endothelial surface (A), whereas the VWF-platelet strings were cleaved in the presence of purified ADAMTS-13 (B). ADAMTS-13 failed to cleave the VWF strings when it was mixed with plasma from acquired TTP containing anti-ADAMTS-13 antibody (E), but functioned normally when mixed with plasma from congenital TTP with deficient ADAMTS-13 activity (D). Panel E is the summary of multiple sample analyses, and results are expressed as means ± SEM, n = 3.     Discussion Top Abstract Introduction Patients, materials, and... Results Discussion References In the current study, we demonstrate that newly released ULVWF forms extremely long stringlike structures on the surface of stimulated endothelium under conditions of flow. These strings support the adhesion of platelets or GP Ib-IX complex-expressing CHO cells and are rapidly cleaved in the presence of normal plasma or partially purified ADAMTS-13 metalloprotease but not in the presence of plasma from patients with the microvascular thrombotic disorder TTP. ULVWF multimers derived from ECs are hyperreactive and capable of interacting under static conditions with platelet GP Ib-IX-V complexes in the absence of ristocetin or botrocetin. ULVWF multimers are also more reactive with platelet receptors in the presence of high fluid shear stress. It had been postulated that this increased platelet reactivity of the ULVWF multimers resulted from a larger number of GP Ib binding sites, sites contained within the A1 domain of VWF. However, our recent studies using optical tweezer technology demonstrated that the ULVWF multimers, in fact, form spontaneous high-strength bonds with GP Ib under conditions in which the plasma forms of VWF fail to bind GP Ib at all.21 The individual bonds between A1 domains within ULVWF multimers and GP Ib were 1.5 times stronger than those between A1 domains in plasma VWF and GP Ib in the presence of modulators. The hyperreactivity of EC-derived ULVWF multimers was also demonstrated in this studyrather than the rolling interaction observed when platelets in flowing blood adhere to plasma VWF,22-24 platelets that attached to ULVWF strings were firmly adherent and were never demonstrated to roll on the strings, even at shear stresses as high as 50 dyne/cm.2 One of the surprising findings of our current study was the extraordinary lengths of the ULVWF multimer strings that formed on the endothelial surface, some reaching several millimeters in length (Figure 2, for example). The length of these ULVWF multimers is much greater than that demonstrated for plasma-derived VWF by rotary shadowing electron microscopy.25 This finding may represent the true length of a single, covalently bound multimerwhich in molecular dimensions would rival some of the largest biologic molecules knownor alternatively could result from noncovalent self-association of VWF multimers, either in the Weibel-Palade bodies or after secretion, as has been demonstrated for surface-associated plasma forms of VWF.26 It should be noted that we never observed the step-wise growth of the stringlike structures, as might be expected if additional multimers were being sequentially added from the newly released ULVWF. The difficulty in estimating the molecular masses of the largest multimeric forms of VWF by conventional means such as agarose gel electrophoresis renders estimation of ULVWF size problematic. Whatever the true size of ULVWF multimers, they typically undergo ADAMTS-13-catalyzed proteolysis on their release from endothelial cells.6 To date, this process has only been studied by using in vitro static assays.8-10 With the use of these techniques, the VWF-cleaving metalloprotease activity in plasma requires prolonged incubation (up to 24 hours) with large or unusually large VWF multimers and nonphysiologic conditions. This finding suggests that conditions absent in the in vitro assay allow much more rapid cleavage in vivo, a conclusion supported by the rapid in vivo clinical response of TTP patients to infusion/exchange using plasma products containing ADAMTS-13.25 A recent report by Andre et al27 described GP Ib-mediated platelet adhesion in vivo to mouse venular endothelium stimulated with either the calcium ionophore A23187 or histamine. This process was dependent on the release of stored VWF from the endothelial cells, as it did not occur in VWF-deficient mice. Of interest, platelet adhesion to the stimulated endothelium began within 15 seconds of stimulation and peaked after about 1 minute, with a subsequent rapid drop-off in the number of adherent platelets. This phenomenon may represent a process in which the capacity of plasma ADAMTS-13 to cleave newly released ULVWF multimers is overwhelmed, allowing the ULVWF multimers to remain transiently on the endothelial surface where they can support platelet adhesion. In contrast to our findings, Andre et al27 observed some of the platelets translocating on the VWF. Our studies suggest possible mechanisms for rapid and efficient ULVWF multimer cleavage in vivo. In the absence of VWF-cleaving metalloprotease activity, ULVWF multimers from stimulated ECs formed long stringlike structures under shear stresses similar to those in both the venous and the partially obstructed arterial circulation. The strings were cleaved rapidly (seconds to 2 minutes) in the presence of plasma ADAMTS-13. This accelerated cleavage of ULVWF multimers in our system as compared with previously described static systems may result either from the presence of the endothelial cell surface, which could provide an anchor or cofactors for the metalloprotease, or from the presence of fluid shear stresses that impart tensile stretch to the EC-bound multimers. Even a low level of fluid shear stress may allow the ULVWF multimers to adopt an extended conformation that exposes the cleavage sites or, alternatively, optimizes EC or ULVWF binding of the metalloprotease. In either case, our studies suggest that rapid and efficient cleavage of EC-derived ULVWF multimers by ADAMTS-13 occurs on EC surfaces. Failure to cleave ULVWF multimers has dangerous clinical consequences in TTP. The ULVWF multimer strings with adherent and aggregated platelets may occlude small blood vessels in situ. ULVWF-platelet clumps may also dislodge under high shear stress and obstruct smaller vessels downstream. Furthermore, platelets could be activated on adhesion and release proinflammatory substances with the potential to activate or damage endothelial cells. The cleavage of ULVWF on the endothelial surface raises the possibility that ADAMTS-13 may have to anchor to the endothelial surface to be fully functional, although direct evidence for this mechanism is lacking. If anchorage is necessary for activity, defects in anchorage could inhibit ADAMTS-13 activity, with the static enzyme assay likely to report normal or moderately compromised VWF protease activity. In accord with this possibility, a report was recently published about a patient with a familial type of relapsing TTP and normal ADAMTS-13 activity in plasma.28 This patient may have a defect in ADAMTS-13 attachment to EC surfaces in vivo. One possible means by which ADAMTS-13 could attach to EC surfaces is through its thrombospondin-1-like domains interacting with endothelial CD36. This possibility would provide a pathophysiologic mechanism by which antibodies to CD36, a thrombospondin-1 receptor on stimulated ECs, could cause acquired TTP, as has been recently reported.29 It is not yet known if toxin- or chemical-induced defects in the attachment of ADAMTS-13 to ECs contributes to the pathophysiology of the hemolytic-uremic syndrome or chemotherapy/transplantation-associated microangiopathy, which are other microvascular thrombotic microangiopathies not accompanied by severe reduction in plasma ADAMTS-13 activity.     Footnotes Submitted May 15, 2002; accepted July 5, 2002. Prepublished online as Blood First Edition Paper, July 25, 2002; DOI 10.1182/blood-2002-05-1401. Supported by grants HL64796, 1-P50-HL65967, and HL18673 from the National Institutes of Health; a Grant-in-Aid from the American Heart Association-Texas Affiliate; and the Mary R. Gibson Foundation. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Jing-fei Dong, Thrombosis Research Section, Department of Medicine, BCM286, N1319, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030; e-mail: jfdong{at}bcm.tmc.edu.     References Top Abstract Introduction Patients, materials, and... Results Discussion References 1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424[CrossRef][Medline] [Order article via Infotrieve]. 2. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983;258:2065-2067[Abstract/Free Full Text]. 3. van de Ven WJ, Voorberg J, Fontijn R, et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep. 1990;14:265-275[CrossRef][Medline] [Order article via Infotrieve]. 4. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435[Medline] [Order article via Infotrieve]. 5. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063[Abstract/Free Full Text]. 6. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666[Abstract/Free Full Text]. 7. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654-1661[Abstract/Free Full Text]. 8. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234[Abstract/Free Full Text]. 9. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88:774-782[Medline] [Order article via Infotrieve]. 10. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72:341-348[CrossRef][Medline] [Order article via Infotrieve]. 11. Allford SL, Machin SJ. Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura. J Clin Pathol. 2000;53:497-501[Free Full Text]. 12. Baker KR, Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Curr Opin Pediatr. 2000;12:23-28[CrossRef][Medline] [Order article via Infotrieve]. 13. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med. 1989;87:9N-15N[CrossRef][Medline] [Order article via Infotrieve]. 14. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461[Medline] [Order article via Infotrieve]. 15. Takahashi K, Sawasaki Y, Hata J, Mukai K, Goto T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev Biol. 1990;26:265-274[Medline] [Order article via Infotrieve]. 16. Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, López JA. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood. 2001;97:162-168[Abstract/Free Full Text]. 17. Dong J, Ye P, Schade AJ, et al. Tyrosine sulfation of glycoprotein Ib. Role of electrostatic interactions in von Willebrand factor binding. J Biol Chem. 2001;276:16690-16694[Abstract/Free Full Text]. 18. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996;88:1525-1541[Free Full Text]. 19. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594[Abstract/Free Full Text]. 20. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584[Abstract/Free Full Text]. 21. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99:3971-3977[Abstract/Free Full Text]. 22. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297[CrossRef][Medline] [Order article via Infotrieve]. 23. Fredrickson BJ, Dong JF, McIntire LV, López JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood. 1998;92:3684-3693[Abstract/Free Full Text]. 24. Dong J, Schade AJ, Romo GM, et al. Novel gain-of-function mutations of platelet glycoprotein Ib by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem. 2000;275:27663-27670[Abstract/Free Full Text]. 25. Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping "plague." Annu Rev Med. 2002;53:75-88[CrossRef][Medline] [Order article via Infotrieve]. 26. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A. 2002;99:425-430[Abstract/Free Full Text]. 27. Andre P, Denis CV, Ware J, et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322-3328[Abstract/Free Full Text]. 28. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994;88:816-825[Medline] [Order article via Infotrieve]. 29. Savasan S, Taub JW, Buck S, Botterill M, Furlan M, Ravindranath Y. Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease. J Pediatr Hematol Oncol. 2001;23:364-367[CrossRef][Medline] [Order article via Infotrieve]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. N. Vomund and E. M. Majerus ADAMTS13 Bound to Endothelial Cells Exhibits Enhanced Cleavage of von Willebrand Factor J. Biol. Chem., November 6, 2009; 284(45): 30925 - 30932. [Abstract] [Full Text] [PDF] Q. Zhang, Y.-F. Zhou, C.-Z. Zhang, X. Zhang, C. Lu, and T. A. Springer Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor PNAS, June 9, 2009; 106(23): 9226 - 9231. [Abstract] [Full Text] [PDF] X. Zhang, K. Halvorsen, C.-Z. Zhang, W. P. Wong, and T. A. Springer Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor Science, June 5, 2009; 324(5932): 1330 - 1334. [Abstract] [Full Text] [PDF] R. de Groot, A. Bardhan, N. Ramroop, D. A. Lane, and J. T. B. Crawley Essential role of the disintegrin-like domain in ADAMTS13 function Blood, May 28, 2009; 113(22): 5609 - 5616. [Abstract] [Full Text] [PDF] K. Vanhoorelbeke, H. B. Feys, and S. F. De Meyer ADAMTS13's tail tale Blood, May 21, 2009; 113(21): 5039 - 5040. [Full Text] [PDF] T. D. Nightingale, K. Pattni, A. N. Hume, M. C. Seabra, and D. F. Cutler Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells Blood, May 14, 2009; 113(20): 5010 - 5018. [Abstract] [Full Text] [PDF] Q. de Mast, E. Groot, P. B. Asih, D. Syafruddin, M. Oosting, S. Sebastian, B. Ferwerda, M. G. Netea, P. G. de Groot, A. J. A. M. van der Ven, et al. ADAMTS13 Deficiency with Elevated Levels of Ultra-Large and Active von Willebrand Factor in P. falciparum and P. vivax Malaria Am J Trop Med Hyg, March 1, 2009; 80(3): 492 - 498. [Abstract] [Full Text] [PDF] D. F. Cutler Fishing for platelets Blood, February 12, 2009; 113(7): 1397 - 1398. [Full Text] [PDF] J. Huang, R. Roth, J. E. Heuser, and J. E. Sadler Integrin {alpha}v{beta}3 on human endothelial cells binds von Willebrand factor strings under fluid shear stress Blood, February 12, 2009; 113(7): 1589 - 1597. [Abstract] [Full Text] [PDF] M. Galbusera, M. Noris, and G. Remuzzi Inherited thrombotic thrombocytopenic purpura Haematologica, February 1, 2009; 94(2): 166 - 170. [Full Text] [PDF] M. D. Gardner, C. K. N. K. Chion, R. de Groot, A. Shah, J. T. B. Crawley, and D. A. Lane A functional calcium-binding site in the metalloprotease domain of ADAMTS13 Blood, January 29, 2009; 113(5): 1149 - 1157. [Abstract] [Full Text] [PDF] A. K. Chauhan, J. Kisucka, A. Brill, M. T. Walsh, F. Scheiflinger, and D. D. Wagner ADAMTS13: a new link between thrombosis and inflammation J. Exp. Med., September 1, 2008; 205(9): 2065 - 2074. [Abstract] [Full Text] [PDF] M. S. Buzza, J. M. Dyson, H. Choi, E. E. Gardiner, R. K. Andrews, D. Kaiserman, C. A. Mitchell, M. C. Berndt, J.-F. Dong, and P. I. Bird Antihemostatic Activity of Human Granzyme B Mediated by Cleavage of von Willebrand Factor J. Biol. Chem., August 15, 2008; 283(33): 22498 - 22504. [Abstract] [Full Text] [PDF] D. D. Wagner and P. S. Frenette The vessel wall and its interactions Blood, June 1, 2008; 111(11): 5271 - 5281. [Abstract] [Full Text] [PDF] B. Hohenstein, A. Braun, K. U. Amann, R. J. Johnson, and C. P. M. Hugo A murine model of site-specific renal microvascular endothelial injury and thrombotic microangiopathy Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1144 - 1156. [Abstract] [Full Text] [PDF] B.-J. H. van den Born, N. V. van der Hoeven, E. Groot, P. J. Lenting, J. C.M. Meijers, M. Levi, and G. A. van Montfrans Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension Hypertension, April 1, 2008; 51(4): 862 - 866. [Abstract] [Full Text] [PDF] A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF] B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF] R.-H. Huang, Y. Wang, R. Roth, X. Yu, A. R. Purvis, J. E. Heuser, E. H. Egelman, and J. E. Sadler Assembly of Weibel Palade body-like tubules from N-terminal domains of von Willebrand factor PNAS, January 15, 2008; 105(2): 482 - 487. [Abstract] [Full Text] [PDF] K. Shim, P. J. Anderson, E. A. Tuley, E. Wiswall, and J. Evan Sadler Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress Blood, January 15, 2008; 111(2): 651 - 657. [Abstract] [Full Text] [PDF] J. Song, K. A Lee, T. S. Park, R. Park, and J. R. Choi Linear Relationship between ADAMTS13 Activity and Platelet Dynamics Even Before Severe Thrombocytopenia Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 368 - 375. [Abstract] [Full Text] [PDF] D. J. Metcalf, T. D. Nightingale, H. L. Zenner, W. W. Lui-Roberts, and D. F. Cutler Formation and function of Weibel-Palade bodies J. Cell Sci., January 1, 2008; 121(1): 19 - 27. [Abstract] [Full Text] [PDF] H. Choi, K. Aboulfatova, H. J. Pownall, R. Cook, and J.-f. Dong Shear-induced Disulfide Bond Formation Regulates Adhesion Activity of von Willebrand Factor J. Biol. Chem., December 7, 2007; 282(49): 35604 - 35611. [Abstract] [Full Text] [PDF] P. Zhang, W. Pan, A. H. Rux, B. S. Sachais, and X. L. Zheng The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow Blood, September 15, 2007; 110(6): 1887 - 1894. [Abstract] [Full Text] [PDF] K. C. Desch and D. G. Motto Thrombotic Thrombocytopenic Purpura in Humans and Mice Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1901 - 1908. [Abstract] [Full Text] [PDF] Z. M. Ruggeri and G. L. Mendolicchio Adhesion Mechanisms in Platelet Function Circ. Res., June 22, 2007; 100(12): 1673 - 1685. [Abstract] [Full Text] [PDF] H. L. Zenner, L. M. Collinson, G. Michaux, and D. F. Cutler High-pressure freezing provides insights into Weibel-Palade body biogenesis J. Cell Sci., June 15, 2007; 120(12): 2117 - 2125. [Abstract] [Full Text] [PDF] T. C. Nguyen, A. Liu, L. Liu, C. Ball, H. Choi, W. S. May, K. Aboulfatova, A. L. Bergeron, and J.-f. Dong Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis Haematologica, January 1, 2007; 92(1): 121 - 124. [Abstract] [Full Text] [PDF] S. M. T. Serrano, J. Kim, D. Wang, B. Dragulev, J. D. Shannon, H. H. Mann, G. Veit, R. Wagener, M. Koch, and J. W. Fox The Cysteine-rich Domain of Snake Venom Metalloproteinases Is a Ligand for von Willebrand Factor A Domains: ROLE IN SUBSTRATE TARGETING* J. Biol. Chem., December 29, 2006; 281(52): 39746 - 39756. [Abstract] [Full Text] [PDF] J.-J. Wu, K. Fujikawa, B. A. McMullen, and D. W. Chung Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor PNAS, December 5, 2006; 103(49): 18470 - 18474. [Abstract] [Full Text] [PDF] J. A. Lopez Sticky business: von Willebrand factor in inflammation Blood, December 1, 2006; 108(12): 3627 - 3627. [Full Text] [PDF] R. De Cristofaro, F. Peyvandi, L. Baronciani, R. Palla, S. Lavoretano, R. Lombardi, E. Di Stasio, A. B. Federici, and P. M. Mannucci Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF): ENERGETICS AND CONFORMATIONAL EFFECTS ON THE VWF/ADAMTS-13 INTERACTION J. Biol. Chem., October 13, 2006; 281(41): 30400 - 30411. [Abstract] [Full Text] [PDF] D. Shang, X. W. Zheng, M. Niiya, and X. L. Zheng Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts Blood, October 1, 2006; 108(7): 2207 - 2215. [Abstract] [Full Text] [PDF] Z. M. Ruggeri, J. N. Orje, R. Habermann, A. B. Federici, and A. J. Reininger Activation-independent platelet adhesion and aggregation under elevated shear stress Blood, September 15, 2006; 108(6): 1903 - 1910. [Abstract] [Full Text] [PDF] C.-j. Liu, W. Kong, K. Xu, Y. Luan, K. Ilalov, B. Sehgal, S. Yu, R. D. Howell, and P. E. Di Cesare ADAMTS-12 Associates with and Degrades Cartilage Oligomeric Matrix Protein J. Biol. Chem., June 9, 2006; 281(23): 15800 - 15808. [Abstract] [Full Text] [PDF] G. Michaux, T. J. Pullen, S. L. Haberichter, and D. F. Cutler P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies Blood, May 15, 2006; 107(10): 3922 - 3924. [Abstract] [Full Text] [PDF] Y. Shibagaki, M. Matsumoto, K. Kokame, S. Ohba, T. Miyata, Y. Fujimura, and T. Fujita Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1289 - 1292. [Abstract] [Full Text] [PDF] A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner Systemic antithrombotic effects of ADAMTS13 J. Exp. Med., March 20, 2006; 203(3): 767 - 776. [Abstract] [Full Text] [PDF] M. A. Cruz Could shear stress be the answer? Blood, March 15, 2006; 107(6): 2218 - 2218. [Full Text] [PDF] R. Donadelli, J. N. Orje, C. Capoferri, G. Remuzzi, and Z. M. Ruggeri Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood Blood, March 1, 2006; 107(5): 1943 - 1950. [Abstract] [Full Text] [PDF] A. Bonnefoy, K. Daenens, H. B. Feys, R. De Vos, P. Vandervoort, J. Vermylen, J. Lawler, and M. F. Hoylaerts Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13 Blood, February 1, 2006; 107(3): 955 - 964. [Abstract] [Full Text] [PDF] S. Zanardelli, J. T. B. Crawley, C. K. N. C. K. Chion, J. K. Lam, R. J. S. Preston, and D. A. Lane ADAMTS13 Substrate Recognition of von Willebrand Factor A2 Domain J. Biol. Chem., January 20, 2006; 281(3): 1555 - 1563. [Abstract] [Full Text] [PDF] T. Ono, J. Mimuro, S. Madoiwa, K. Soejima, Y. Kashiwakura, A. Ishiwata, K. Takano, T. Ohmori, and Y. Sakata Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure Blood, January 15, 2006; 107(2): 528 - 534. [Abstract] [Full Text] [PDF] S. P. Tull, S. I. Anderson, S. C. Hughan, S. P. Watson, G. B. Nash, and G. E. Rainger Cellular Pathology of Atherosclerosis: Smooth Muscle Cells Promote Adhesion of Platelets to Cocultured Endothelial Cells Circ. Res., January 6, 2006; 98(1): 98 - 104. [Abstract] [Full Text] [PDF] K. Soejima, H. Nakamura, M. Hirashima, W. Morikawa, C. Nozaki, and T. Nakagaki Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood J. Biochem., January 1, 2006; 139(1): 147 - 154. [Abstract] [Full Text] [PDF] Z. Tao, Y. Peng, L. Nolasco, S. Cal, C. Lopez-Otin, R. Li, J. L. Moake, J. A. Lopez, and J.-f. Dong Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions Blood, December 15, 2005; 106(13): 4139 - 4145. [Abstract] [Full Text] [PDF] L. H. Nolasco, N. A. Turner, A. Bernardo, Z. Tao, T. G. Cleary, J.-f. Dong, and J. L. Moake Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers Blood, December 15, 2005; 106(13): 4199 - 4209. [Abstract] [Full Text] [PDF] J. J. J. Hulstein, P. G. de Groot, K. Silence, A. Veyradier, R. Fijnheer, and P. J. Lenting A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B Blood, November 1, 2005; 106(9): 3035 - 3042. [Abstract] [Full Text] [PDF] J. Ai, P. Smith, S. Wang, P. Zhang, and X. L. Zheng The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor J. Biol. Chem., August 19, 2005; 280(33): 29428 - 29434. [Abstract] [Full Text] [PDF] M. Rieger, P. M. Mannucci, J. A. K. Hovinga, A. Herzog, G. Gerstenbauer, C. Konetschny, K. Zimmermann, I. Scharrer, F. Peyvandi, M. Galbusera, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Blood, August 15, 2005; 106(4): 1262 - 1267. [Abstract] [Full Text] [PDF] G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF] Z. Tao, Y. Wang, H. Choi, A. Bernardo, K. Nishio, J. E. Sadler, J. A. Lopez, and J.-f. Dong Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow Blood, July 1, 2005; 106(1): 141 - 143. [Abstract] [Full Text] [PDF] E. M. Majerus, P. J. Anderson, and J. E. Sadler Binding of ADAMTS13 to von Willebrand Factor J. Biol. Chem., June 10, 2005; 280(23): 21773 - 21778. [Abstract] [Full Text] [PDF] M. Noris, S. Bucchioni, M. Galbusera, R. Donadelli, E. Bresin, F. Castelletti, J. Caprioli, S. Brioschi, F. Scheiflinger, G. Remuzzi, et al. Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1177 - 1183. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, G. Antoine, M. Hermann, M. Rieger, F. Scheiflinger, and B. Lammle Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Blood, January 15, 2005; 105(2): 542 - 544. [Abstract] [Full Text] [PDF] K. Nishio, P. J. Anderson, X. L. Zheng, and J. E. Sadler Binding of platelet glycoprotein Ib{alpha} to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13 PNAS, July 20, 2004; 101(29): 10578 - 10583. [Abstract] [Full Text] [PDF] A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J.-f. Dong Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow Blood, July 1, 2004; 104(1): 100 - 106. [Abstract] [Full Text] [PDF] C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lammle, P. M. Mannucci, and F. Scheiflinger Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura Blood, June 15, 2004; 103(12): 4514 - 4519. [Abstract] [Full Text] [PDF] J. E. Pimanda, T. Ganderton, A. Maekawa, C. L. Yap, J. Lawler, G. Kershaw, C. N. Chesterman, and P. J. Hogg Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice J. Biol. Chem., May 14, 2004; 279(20): 21439 - 21448. [Abstract] [Full Text] [PDF] P. S. Frenette P-selectin and VWF tie the knot Blood, March 15, 2004; 103(6): 1979 - 1980. [Full Text] [PDF] A. Padilla, J. L. Moake, A. Bernardo, C. Ball, Y. Wang, M. Arya, L. Nolasco, N. Turner, M. C. Berndt, B. Anvari, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface Blood, March 15, 2004; 103(6): 2150 - 2156. [Abstract] [Full Text] [PDF] D. J. Bowen and P. W. Collins An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13 Blood, February 1, 2004; 103(3): 941 - 947. [Abstract] [Full Text] [PDF] J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George Recent Advances in Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2004; 2004(1): 407 - 423. [Abstract] [Full Text] [PDF] D. D. Wagner and P. C. Burger Platelets in Inflammation and Thrombosis Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2131 - 2137. [Abstract] [Full Text] [PDF] K. Soejima, M. Matsumoto, K. Kokame, H. Yagi, H. Ishizashi, H. Maeda, C. Nozaki, T. Miyata, Y. Fujimura, and T. Nakagaki ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage Blood, November 1, 2003; 102(9): 3232 - 3237. [Abstract] [Full Text] [PDF] F. Scheiflinger, P. Knobl, B. Trattner, B. Plaimauer, G. Mohr, M. Dockal, F. Dorner, and M. Rieger Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Blood, November 1, 2003; 102(9): 3241 - 3243. [Abstract] [Full Text] [PDF] J.-f. Dong, J. L. Moake, A. Bernardo, K. Fujikawa, C. Ball, L. Nolasco, J. A. Lopez, and M. A. Cruz ADAMTS-13 Metalloprotease Interacts with the Endothelial Cell-derived Ultra-large von Willebrand Factor J. Biol. Chem., August 8, 2003; 278(32): 29633 - 29639. [Abstract] [Full Text] [PDF] T. Romani de Wit, M. G. Rondaij, P. L. Hordijk, J. Voorberg, and J. A. van Mourik Real-Time Imaging of the Dynamics and Secretory Behavior of Weibel-Palade Bodies Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 755 - 761. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2002-05-1401v1 100/12/4033    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dong, J.-f. Articles by López, J. A. Search for Related Content PubMed PubMed Citation Articles by Dong, J.-f. Articles by López, J. A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020